Protara Therapeutics (NASDAQ:TARA) Issues Earnings Results, Beats Expectations By $0.02 EPS

Protara Therapeutics (NASDAQ:TARA) announced its quarterly earnings data on Friday. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.02, FiscalAI reports.

Protara Therapeutics Stock Performance

Protara Therapeutics stock traded up $0.17 during midday trading on Friday, reaching $2.30. 690,546 shares of the stock were exchanged, compared to its average volume of 888,528. Protara Therapeutics has a 52 week low of $2.09 and a 52 week high of $7.82. The firm has a market cap of $135.92 million, a PE ratio of -1.70 and a beta of 1.54. The company’s fifty day moving average is $3.03 and its 200-day moving average is $4.49.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Protara Therapeutics in a research note on Thursday, October 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Protara Therapeutics in a research note on Thursday, October 15th. Finally, Wall Street Zen raised shares of Protara Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, September 5th. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $26.25.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc is a clinical-stage biotechnology company focused on developing transformative therapies for cancer and other serious diseases. The company’s lead product candidate, TARA-002, is an investigational cell-based immunotherapy derived from a proprietary preparation of Streptococcus pyogenes. Protara is evaluating TARA-002 primarily for the treatment of non-muscle-invasive bladder cancer.

Protara has also investigated TARA-002 for lymphatic malformations, rare abnormalities of the lymphatic system that can cause swelling, pain and other complications.